Mar 27 |
PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript
|
Mar 27 |
PAVmed Full Year 2023 Earnings: EPS Beats Expectations
|
Mar 27 |
PAVmed Non-GAAP EPS of -$1.33 beats by $0.47, revenue of $1.05M beats by $0.02M
|
Mar 26 |
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
|
Mar 26 |
PAVmed Q4 2024 Earnings Preview
|
Mar 21 |
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
|
Mar 21 |
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
|
Mar 20 |
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
|
Mar 13 |
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
|
Mar 12 |
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
|